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The tyrosine phosphatase SHP-2 has been implicated in a variety of signaling pathways, including those mediated by
neurotrophins in neurons. To examine the role of SHP-2 in the development of sympathetic neurons, we inhibited the
function of SHP-2 in transgenic mice by overexpressing a catalytically inactive SHP-2 mutant under the control of the
human dopamine -hydroxylase promoter. Expression of mutant SHP-2 did not influence the survival, axon initiation, or
pathfinding abilities of the sympathetic neurons. However, mutant SHP-2 expression resulted in an overproduction of
sympathetic fibers in sympathetic target organs. This was due to interference with SHP-2 function, as overexpression of wild
type SHP-2 had no such effect. In vitro, NGF-dependent neurite growth was inhibited in neurons expressing mutant SHP-2
but not in those expressing wild type SHP-2. Mutant (but not wt) SHP-2 expression also inhibited NGF-stimulated ERK
activation. The NGF-dependent survival pathway was less affected than the neurite growth pathway. Our results suggest
that NGF-regulated axon growth signals, and to a lesser degree survival signals, are mediated through a SHP-2-dependent
pathway in sympathetic neurons. The increased sympathetic innervation in target tissues of neurons expressing mutant
SHP-2 may result from interference with normal “stop” signals dependent on signaling by gradients of NGF. © 2002 Elsevier
Science (USA)
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Protein tyrosine phosphorylation, regulated by the oppos-
ing effects of protein tyrosine kinases (PTKs) and protein
tyrosine phosphatases (PTPs), controls many cellular
events, including the growth and guidance of axons during
development (Chisholm and Tessier-Lavigne, 1999; Desai
et al., 1997). Efforts to understand the signals underlying
the regulation of axon growth have historically focused
mainly on PTKs (Holland et al., 1998; Paves and Saarma,
1997). Recently, the group of transmembrane PTPs known
as receptor protein tyrosine phosphatases has been impli-
cated in the regulation of axon growth decisions (Bixby,
2000). In contrast, little is known about how any cytosolic
PTP influences axonal patterning.
1 To whom correspondence should be addressed. Fax: (305) 243-
2970. E-mail: jbixby@miami.edu.
170Nerve growth factor (NGF) and other neurotrophins pro-
mote neuronal survival, differentiation, and plasticity (Hen-
derson, 1996; Lo, 1995; Snider, 1994). In particular, NGF is
necessary for the normal development of sympathetic neu-
rons, including their survival and axon growth (Hayashi et
al., 1985; Hendry, 1977; Levi-Montalcini, 1976; Thoenen et
al., 1971). Binding of NGF to trkA, a receptor PTK, stimu-
lates several signaling pathways, including at least one that
results in the activation of extracellular signal-regulated
kinases (ERKs; Kaplan and Miller, 2000; Sofroniew et al.,
2001; see also Watson et al., 2001). Evidence both from
sympathetic neurons and from PC12 cells suggests that
activation of ERK is an important step in the induction of
axon growth by NGF (Cowley et al., 1994; Fukuda et al.,
1995). This is in line with recent findings implicating ERK
activation as a central event in the initiation of neuronal
process outgrowth (Perron and Bixby, 1999).SHP-2 is a ubiquitously expressed cytosolic PTP contain-
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ing two tandemly linked SH2 domains (Ahmad et al., 1993;
Feng et al., 1993; Freeman et al., 1992; Pluskey et al., 1995;
Vogel et al., 1993). SHP-2 activity is required for appropriate
transduction of signals originating from a number of cell
surface receptors, including many receptor PTKs (Feng,
1999). In particular, SHP-2 acts downstream of receptors for
EGF, FGF, PDGF, NGF, and insulin and is required for
activation of ERK by these receptors (Bennett et al., 1994,
1996; Milarski and Saltiel, 1994; Noguchi et al., 1994;
Rivard et al., 1995; Yamauchi et al., 1995; Zhao et al.,
1995). Futhermore, interference with SHP-2 activity, in
vitro, inhibits NGF-induced neuronal differentiation of
PC12 cells (Wright et al., 1997). It is therefore reasonable to
hypothesize that SHP-2 could regulate survival and/or axon
growth of sympathetic neurons in vivo, especially those
aspects dependent on NGF.
Targeted deletions of mouse shp-2 result in early embry-
onic lethality, which precludes investigation of potential
abnormalities in neuronal differentiation (Saxton et al.,
1997). We therefore adopted a transgenic strategy in which
a catalytically inactive form of SHP-2 was expressed selec-
tively in sympathetic neurons by using the human dopa-
mine -hydroxylase (hDBH) promoter. The hDBH promoter
construct we used is known to direct transgene expression
to a small subset of cells, including sympathetic neurons,
some neurons in the CNS, and adrenal chromaffin cells.
This hDBH promoter drives expression in sympathetic
neurons from embryonic day 9.5 (E9.5) and is constitutively
expressed in sympathetic neurons (Kapur et al., 1991;
Mercer et al., 1991). This ensures that the SHP-2 transgene
will be expressed in sympathetic neurons commencing
when neural crest cells coalesce into ganglia and prior to
axon outgrowth (Kapur et al., 1991; Rubin, 1985). Expres-
sion of a catalytically inactive SHP-2 has been shown
previously to act as a dominant-interfering mutant, in vitro,
in numerous cell types (Bennett et al., 1994, 1996; Guan
and Dixon, 1991; Milarski and Saltiel, 1994; Noguchi et al.,
1994; Rivard et al., 1995; Yamauchi et al., 1995; Zhao et al.,
1995). Using transgenic mice that express this SHP-2 mu-
tant, we demonstrate that SHP-2 activity is not required for
survival, initial differentiation, or axon outgrowth of sym-
pathetic neurons in vivo but is necessary for normal axon
termination within innervated targets. Further, our data
indicate that SHP-2 activity is necessary for NGF-
dependent neurite growth and ERK activation in sympa-
thetic neurons in vitro and plays a role in NGF-dependent
survival. Our results are consistent with a model in which
gradients of NGF determine the extent of axonal arboriza-
tion in sympathetic targets via a SHP-2-dependent pathway.
MATERIALS AND METHODS
Generation of SHP-2 transgenic mouse lines. A 1.9-kb SHP-2
cDNA (wtSHP-2) containing the full coding region was isolated
from an adult brain cDNA library. A DN SHP-2 mutant (C459S)
was generated by PCR-based site-directed mutagenesis and con-
firmed by sequencing. SHP-2 cDNAs were fused 3 to a 5.8-kb
hDBH promoter and a 171-bp segment spanning the first intron of
the rat insulin II gene, included to boost expression (Palmiter et al.,
1991). A 799-bp portion of the human growth hormone gene
containing a 66-bp coding sequence and a 633-bp 3-untranslated
region (UTR) was added 3 to the SHP-2 cDNA to provide a
polyadenylation signal for mRNA stability and a unique sequence
tag. The constructs were injected into mouse zygotes and trans-
genic founders identified by tail blots (Brinster et al., 1981), using
probes corresponding to the hGH 3 UTR. In established lines,
genotypes were determined by PCR using primers corresponding to
SHP-2 cDNA and the hGH 3 UTR, respectively. Three lines that
expressed wt SHP-2 [OX: TgN(DBH-SHP2)Bmas 2,9,14] and three
that expressed DN SHP-2 [DN: TgN(DBH-SHP2C459S) Bmas
21,31,33] were established, and the phenotypes described were
consistent across each genotype.
SHP-2 Western blot and measures of transgene expression.
Western blots of paired adult mouse superior cervical ganglia
homogenates were prepared as described (Perron and Bixby, 1999),
using a 1:1000 dilution of monoclonal anti-SHP-2 antibody (Trans-
duction Laboratories P54420) followed by anti-mouse alkaline
phosphatase-conjugated secondary antibody (Promega) diluted
1:5000. Two different methods were used to quantify SHP-2 levels
in wt and trangenic SCGs; these agreed well with each other. In the
slope method, optical densities of SHP-2-immunoreactive bands
were plotted against the amount of protein loaded for each SCG
pair, and linear regression was performed for transgenic or wt SCG.
Relative expression was determined by the ratio of the calculated
slopes, transgenic:wt. In some cases, blots were normalized by
reprobing to measure immunoreactive neuron-specific enolase (Fig.
1); in these cases, the SHP-2/NSE ratio was calculated. The average
ratios of SHP-2 protein (tg/wt) in SCGs for the two DN lines and
the two OX lines used for further experiments were: DN 33, 2.4 
0.63; DN 31, 2.04  0.32; OX 14, 2.2  0.56; OX 2, 2.15  0.15.
Most experiments used line 33 for DN SHP-2, and line 14 for OX
SHP-2.
Immunohistochemical procedures. For whole-mount studies
of initial axon growth, mouse embryos (E10.5–E11.5) were col-
lected (yolk sacs were genotyped) and fixed in freshly prepared 2%
paraformaldehyde. Endogenous peroxidase activity was blocked by
incubation in 5% H2O2/methanol for 5–8 h at room temperature,
depending on embryo size. Rehydrated embryos were incubated in
blocking solution (0.5% Triton X-100, 2% nonfat dry milk in PBS)
followed by a 1:100 dilution of the monoclonal anti-neurofilament
antibody (Sigma, N5264) in blocking solution, overnight at 4°C.
After repeated washes, antibody was detected by HRP-conjugated
goat anti-mouse IgG (Promega) diluted 1:800. Fresh submaxillary
glands from adult mice were fixed in 3% paraformaldehyde and
embedded in OCT. Tissue sections (15 m) were incubated over-
night in a 1:100 dilution of polyclonal anti-TH antibody (Pel Freez
P40101-0), and bound antibody was detected by goat anti-rabbit IgG
Alexa488 diluted 1:200. We examined TH staining in three wt
mice, three DN SHP-2 mice, and two OX SHP-2 mice.
Histology of sympathetic ganglia. SCGs were dissected from
6-month-old mice, fixed in 10% neutral-buffered formalin over-
night, dehydrated, and equilibrated with xylene. Paraffin-
embedded tissue sections (6 m) were defatted, rehydrated, and
stained with hematoxylin (Sigma MHS-16) and eosin Y (Sigma
HT110-1-16). Photomicrographs were analyzed by using NIH Im-
age software. Neuron density was obtained by calculating the ratio
of neuron nuclei to the cross-sectional area of a selected field.
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Ganglion size was estimated from the surface areas of sections
from the midpoint (largest diameter) of each ganglion.
Catecholamine histofluorescence. Submaxillary glands and pi-
neal glands were removed from adult female mice, with or without
intraperitoneal injection of 100 g of -methyl norepinephrine in 1
mM ascorbic acid 1 h before dissection. Fresh tissue was embedded
in OCT and frozen in liquid nitrogen. Tissue sections (15 m) were
cut and mounted onto slides, and catecholamine histofluorescence
was produced as described (De la Torre, 1980). Sections were air
dried and heated in oil to 100°C, then coverslipped and viewed by
epifluorescence. Fluorescence images were quantified by using
NIH Image. Overall, we examined catecholamine histofluores-
cence in submaxillary glands from 12 wt mice, 14 DN SHP-2 mice,
and 9 OX SHP-2 mice; and pineal glands from 2 wt mice and 2 DN
SHP-2 mice. Results in all cases were consistent with the data
reported.
Mouse SCG culture and neurite outgrowth assay. Neonatal
(P0) mouse SCG were dissected, partially dissociated in 0.35%
trypsin solution, and cultured on coverslips precoated with poly-
D-lysine and laminin as described (Perron and Bixby, 1999). L15
culture medium (Life Technologies), containing 5% rat serum and
various vitamins, was supplemented with 100 ng/ml NGF-
(Sigma, N2513) or with NGF plus 100 ng/ml each of BDNF and
NT-3 (Peprotech). Neurite lengths were measured from video
images by using SigmaScan (Jandel Scientific) or NIH Image soft-
ware.
Phospho-ERK immunocytochemistry and Western blotting. P0
SCG neurons were isolated and cultured as described above for 6
days. NGF was removed, and the cultures were incubated a further
12 h prior to readdition of 100 ng/ml NGF- (or no addition in
controls). Cultures were fixed 3 h later, then incubated overnight in
a 1:100 dilution of phosphospecific ERK1/ERK2 antibody (New
England Biolabs 9101S) using Rhodamine-conjugated goat-anti-
rabbit IgG (Sigma) as a secondary antibody. ERK staining was
quantified by scoring each neuron identified under phase-contrast
optics as having fluorescent ERK staining either clearly greater
than controls (which had no NGF readdition) or indistinguishable
from controls. At least 70 neurons were scored for each condition
in each experiment. For Western blots, protein extracts prepared
from cultures treated as above were subjected to SDS-PAGE and
transferred to nitrocellulose. The membranes were probed with the
phosphospecific ERK antibody prior to stripping and reprobing with
a pan-ERK antibody.
RESULTS
Creation of SHP-2 Transgenic Mice
To study the biological function of SHP-2 in sympathetic
neurons in vivo, a SHP-2 transgene was overexpressed in
sympathetic neurons by using a promoter region of the
human dopamine--hydroxylase (hDBH) gene (Fig. 1A). The
hDBH promoter has previously been shown to direct ex-
pression to sympathetic neurons in transgenic mice (Kapur
et al., 1991; Mercer et al., 1991). Two types of SHP-2
transgene were introduced into the mouse genome: a cDNA
encoding wild-type SHP-2 (wtSHP-2) and one encoding a
catalytically inactive (DN) SHP-2 in which an essential
cysteine (C459) residue is mutated to serine. Overexpres-
sion of the catalytically inactive mutant, in vitro, has been
FIG. 1. Production of SHP-2 transgenic mice. (A) DNA construct used to generate SHP-2 transgenic mice. A 5.8-kb regulatory sequence
from the human dopamine -hydroxylase gene (hDBH) drives expression of a 1.9-kb SHP-2 wild type or Cys3Ser mutant cDNA. rI, 171-bp
segment spanning the first intron of rat insulin II gene; hGH, 799-bp portion of the human growth hormone gene. (B) The SHP-2 transgene
detected by dot blot of mouse tail DNA with the hGH sequences or by genomic PCR using a primer pair corresponding to the SHP-2 cDNA
and the hGH tag, respectively. (Left) 3/5 mice in a litter carry the transgene (lanes 1, 2, 5). (Right) 4/7 mice in a litter were identified as
transgenic by genomic PCR (lanes 1, 4, 5, 7). Lanes 3, 4 (left) and 2, 3, 6 (right) contain DNA from wt littermates. (C) SHP-2 protein is
overexpressed in superior cervical ganglia (SCGs) from transgenic animals. (Left) 8 g of protein from a pair of wt or DN SCGs was run on
SDS PAGE and detected on a Western blot with anti-SHP-2 antibody. (Right) 5 g of protein from a pair of wt or OX SCGs was run on SDS
PAGE and detected on a Western blot with anti-SHP-2 antibody. After quantification of these bands, blots was reprobed with
anti-neuron-specific enolase (NSE) for normalization. In each case, quantitative analysis showed that the transgenic ganglia had a
SHP-2/NSE ratio of roughly 2.5. Quantification of blots (n  3 for each line), using both this normalization method and the slope method
(see Materials and Methods) showed that SCGs from both DN and OX lines consistently contained 2-2.5 times normal levels of
immunoreactive SHP-2.
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shown to inhibit endogenous SHP-2 function (Guan and
Dixon, 1991; Hadari et al., 1998; Noguchi et al., 1994;
Wright et al., 1997). Overexpression of wt SHP-2 was used
as a control to distinguish between phenotypes resulting
from inhibition of SHP-2 function and those resulting from
aberrant increases in SHP-2 protein (potentially mediated
by nonphosphatase domains). The presence of the SHP-2
transgene was detected by using dot blots of total nucleic
acid from tail biopsies or by PCR (Fig. 1B). Three indepen-
dent SHP-2 transgenic lines were established for the SHP-2
mutant (referred to as DN lines) as well as for the wtSHP-2
(referred to as overexpresser or OX lines). Western blots of
adult SCG protein extracts revealed increased levels of
SHP-2 protein in all transgenic lines (Fig. 1C, and data not
shown). Quantitative analysis (see Materials and Methods)
demonstrated that SHP-2 protein in SCG isolated from
either DN or OX lines was 2-2.5 times that in nontrans-
genic littermates. Because the antibody used could not
distinguish between endogenous SHP-2 and the transgenic
protein, it can only be assumed that levels of transgene-
generated SHP-2 were 100–150% those of the endogenous
protein. This assumption is reasonable, because in PC12
cells, two- to threefold overexpression of SHP-2 does not
influence expression of endogenous SHP-2 (Wright et al.,
1997).
Sympathetic Neurons Expressing DN SHP-2
Survive and Differentiate
Expression of transgenes using the hDBH promoter com-
mences before E9.5 and is constitutive in later embryos and
adults (Kapur et al., 1991; Mercer et al., 1991). To investi-
gate the consequence of inhibiting SHP-2 activity during
the development of sympathetic neurons, we first exam-
ined the morphology of SCGs from wt and DN SHP-2 adult
mice. The overall appearance of the SCG was similar in wt
and DN animals (Fig. 2). No differences with respect to
either neuronal size or density were observed between
SHP-2 DN and wt SCG. Both wt and DN ganglia contained
large ovoid neurons of equivalent size, with an average long
axis diameter of 19.08  0.91 m (mean  SEM) for the wt
and 18.77  0.56 m for the DN neurons, and an average
short axis diameter of 14.01  0.60 m for the wt and
13.46  0.47 m for the DN (200 neurons measured per
condition). Small round neurons (longest axis 15 m),
usually near the perimeter of the ganglia, had equivalent
diameters averaging 11.99 0.36 m for the wt and 12.31
0.34 m for the DN (200 neurons per condition). Neuron
densities (see Materials and Methods) measured using me-
dial transverse sections showed no significant differences
between ganglia from wt and DN mice [12.57  1.44
arbitrary units (AU), wt; 12.92  1.19 AU, DN; 600
neurons per condition]. As the average sizes of the medial
transverse sections from DN SCGs were indistinguishable
from wt (not shown), the number of neurons per SCG was
not significantly altered by expression of DN SHP-2. There-
fore, expression of DN SHP-2 did not appear to interfere
with proliferation, morphological maturation, or survival of
neurons in the SCG. As we did not obtain exact counts of
neurons, small differences in neuron number might not be
discovered by our techniques.
We also examined initial axon outgrowth from DN SHP-2
sympathetic neurons using neurofilament staining of
whole-mount embryos. In these experiments, we found no
differences in the pattern of axon outgrowth between wt
FIG. 2. SCGs from SHP-2 DN mice have a normal morphology. SCGs from wild type (A) and SHP-2 DN (B) mice were fixed, sectioned
at 6 m, and stained with hematoxylin/eosin. The SHP-2 DN SCG is similar to the wild type control in the number, size, and density of
neurons. Similar results were seen in several ganglia. Scale bar, 100 m.
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FIG. 3. Increased sympathetic innervation of submaxillary glands in SHP-2 DN mice. Sympathetic innervation of submaxillary glands was
examined by using antibody to tyrosine hydroxlase (TH), detected with secondary antibodies labeled with Alexa488. (A) In wt mice,
individual acini from submaxillary glands are surrounded by TH-positive nerve fibers. (B) In SHP-2 DN glands, staining is noticeably
brighter throughout the tissue. (C, D) At higher magnification, an increased number of TH-positive nerve fibers can be seen in the SHP-DN
tissue (D), compared with the wt (C). (E) and (F) are TH immunostaining and phase contrast views, respectively, of a DN SHP-2 section at
low power. White arrows point to corresponding points in the two micrographs. Scale bar, 30 m (A, C); 100 m (E). In this and subsequent
figures showing fluorescent images, different tissues were processed together, photographs were taken at the same time under identical
illumination conditions, and these were processed identically to facilitate comparison. Representative sections are shown.
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FIG. 4. Increased sympathetic innervation of submaxillary glands in SHP-2 DN mice, but not in SHP-2 OX mice. Sympathetic innervation
of submaxillary glands was examined by using the glyoxylic acid method for catecholamine histofluorescence. (A, D) Wt (A) and SHP-2 DN
(D) gland sections in control conditions. There is increased catecholamine fluorescence in the DN tissue. (B, E) Wt (B) and SHP-2 DN (E)
gland sections following injection of -methyl norepinephrine to saturate catecholamine levels. The increased catecholamine fluorescence
in the DN is even more evident, suggesting that the increased levels are due to more sympathetic fibers, rather than increased NE levels
in the fibers. Examples shown are representative of multiple experiments (n  4) on each of three SHP-2 DN lines. (C, F) Wt (C) and SHP-2
OX (F) gland sections following injection of -methyl norepinephrine to saturate catecholamine levels. Levels of catecholamine
fluorescence in the OX gland is similar to that seen in the wt gland. Examples shown are representative of multiple experiments (n  4)
on each of 2 SHP-2 OX lines. Scale bar, 30 m.
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and DN SHP embryos when embryos of E10.5–E11.5 were
examined (n  2 embryos wt; 2 embryos, DN SHP-2; data
not shown). This age represents the period of axon out-
growth from sympathetic neurons during embryogenesis.
Therefore, it is unlikely that overexpression of a DN
mutant form of SHP-2 hindered survival, differentiation, or
initial axon outgrowth of sympathetic neurons. Although
the caliber of axon tracts did not appear different between
DN SHP-2 and wt, small effects on numbers of axons in
sympathetic nerves would not be seen by our methods.
Expression of DN SHP-2 Leads to Increased
Sympathetic Innervation in Submaxillary Glands
Our hypothesis that SHP-2 is required for normal axon
growth and guidance predicts that DN SHP-2 expression
will lead to defects in sympathetic target innervation. To
investigate this possibility, we visualized the distribution
of sympathetic fibers in target tissues from adult wt and
SHP-2 DN mice using tyrosine hydroxylase (TH) immuno-
staining. TH-positive fibers were seen around the periphery
of individual acini, as expected (Figs. 3A, 3E, and 3F).
Surprisingly, the density of TH-immunoreactive fibers in
DN submaxillary glands was considerably more intense
than in the wt glands (Fig. 3B), suggesting either an increase
in the density of ramifying sympathetic fibers or a higher
level of TH protein in the DN glands. At higher magnifica-
tion, it appeared that the DN glands had increased numbers
of sympathetic fibers (Figs. 3C and 3D), though this impres-
sion was not quantified.
To confirm the apparent increase in sympathetic inner-
vation density in SHP-2 DN glands, we examined the
distribution of sympathetic fibers in adult mice using
catecholamine histofluorescence. Although this technique
was slightly less sensitive than TH immunostaining in our
hands, we found a similar increase in fiber-related fluores-
cence in the DN glands, with fluorescent fibers both more
intense and more widely distributed than in wt glands (Figs.
4A and 4D). No difference in fluorescence was seen in
glands from SHP-2 OX mice compared with controls (data
not shown), indicating that this effect was due to inhibition
of SHP-2 catalytic function rather than overexpression of
other SHP-2 domains.
Similar to the situation for TH staining, increased cate-
cholamine histofluorescence in the DN SHP-2 submaxil-
lary glands might be due to a change in catecholamine
metabolism of sympathetic fibers, rather than a change in
the density of sympathetic nerve growth. To address this
issue, we injected a norepinephrine analog (-methyl nor-
epinephrine) into the peritoneal cavity of mice 1 h before
dissection. This procedure loads sympathetic axons and
terminals with maximum concentrations of catecholamine
(ElShamy et al., 1996), allowing for direct comparisons of
sympathetic fiber densities in wt and DN SHP-2 glands.
Injection of -methyl norepinephrine increased catechol-
amine histofluorescence in both DN and wt submaxillary
glands, as expected. However, the increased distribution of
fluorescence in the DN SHP-2 compared with the control
glands was even more evident (Figs. 3B and 3E). Examina-
tion of SHP-2 OX submaxillary glands after injection of
-methyl norepinephrine again revealed no differences be-
tween OX and wt glands (Figs. 3C and 3F). Thus, the
increased catecholamine fluorescence in DN SHP-2 glands
likely reflects an increased level of sympathetic innervation
due to inhibition of SHP-2 activity in the sympathetic
neurons.
Quantification of fluorescence levels in wt and transgenic
submaxillary glands (after -methyl norepinephrine treat-
ment) confirmed these qualitative impressions. While the
average fluorescence level above background in DN SHP-2
glands was 5.1  1.4-fold that in wt littermates (n  2
animals), the average level in OX SHP-2 glands was 0.99 
0.05-fold that of wt (n  2 animals). Therefore, using two
separate measures, inhibition of SHP-2 activity in sympa-
thetic neurons led to increased densities of sympathetic
innervation in the submaxillary gland. Thus, SHP-2 activity
appears to be required in a signaling pathway that regulates
sympathetic innervation of the submaxillary gland.
Expression of DN SHP-2 Leads to Increased
Innervation of Pineal Glands
To determine whether increased sympathetic innerva-
tion of target organs in DN SHP-2 mice was limited to the
submaxillary gland, we used catecholamine histofluores-
cence to examine sympathetic innervation of pineal glands,
which receive predominant innervation from the SCG
(Karasek, 1983). To obviate differences due to changing
levels of norepinephrine, wt and DN SHP-2 mice were
injected intraperitoneally with -methyl norepinephrine
1 h before removing the glands. A clear and reproducible
increase in catecholamine fluorescence in DN SHP-2 pineal
glands compared with wt was observed (Fig. 5, and data not
shown). Therefore, inhibition of SHP-2 function leads to
increased terminal innervation of pineal as well as submax-
illary glands. These results demonstrate that the DN effects
on target innervation are not limited to a single target
organ, but may be general among sympathetic targets.
Thus, inhibiting SHP-2 activity in sympathetic neurons
does not affect neuronal survival, initial axon outgrowth, or
the ability to reach target organs, but leads to abnormally
dense innervation of target organs. These results are con-
sistent with the idea that SHP-2 activity is required for
regulation of axon growth by NGF, as innervation within
targets, but not initial axon growth to targets, appears to
depend on an NGF gradient (Hoyle et al., 1993).
DN SHP-2 Inhibits NGF-Dependent Neurite
Growth from Cultured SCG Neurons
Interference with SHP-2 function in PC-12 cells, through
overexpression of DN SHP-2, inhibits NGF-induced neuro-
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nal differentiation of PC12 cells, as assessed by reduced
neurite outgrowth (Wright et al., 1997). As PC12 cells are
thought to be a model for sympathetic neurons (Greene and
Tischler, 1976), this result suggests that expression of DN
SHP-2 should inhibit neurite growth from sympathetic
neurons, which is NGF-dependent in vitro (Coughlin et al.,
1977; Coughlin and Collins, 1985). To test this idea, we
examined NGF-induced axon outgrowth from wt and
SHP-2 transgenic sympathetic neurons in vitro. Neonatal
SCGs were dissected, partially dissociated, and cultured on
poly-D-lysine/laminin substrates in medium supplemented
with 100 ng/ml NGF, a concentration demonstrated to be
supramaximal for survival and differentiation of sympa-
thetic neurons in vitro (Coughlin and Collins, 1985; Mizel
and Bamburg, 1976). Dissociated wt SCG neurons grew
numerous long neurites after 24 h; some neurites inter-
twined to form a meshwork (Fig. 6A). In contrast, DN
SHP-2 SCG neurons rarely extended neurites, and those
neurites that formed were extremely short (Fig. 6E). Inhibi-
tion of neurite growth by DN SHP-2 was also clearly
observed in SCG explants, in which both cell–cell interac-
tions and neurite fasciculation were maintained. DN SHP-2
SCG explants had many fewer and shorter neurites com-
pared with wt explants of similar area (Figs. 6B and 6F).
Despite these differences in neurite growth, the appearance
of dissociated neurons, as well as the size and appearance of
explants, were comparable in wt and DN SHP-2 cultures.
Inhibition of neurite growth from SCG neurons might in
principle be due to overexpression of SHP-2 per se, rather
than a dominant negative effect. To examine this possibil-
ity, neurite growth from SHP-2 OX sympathetic neurons
was examined under the same culture conditions. No clear
differences in neurite outgrowth between OX SHP-2 and wt
controls could be detected. This was true whether we
examined dissociated neurons (Figs. 6C and 6G) or gangli-
onic explants (Figs. 6D and 6H). These results indicate that
the robust inhibition of neurite formation seen in DN
SHP-2 sympathetic neuron cultures is due to a dominant-
negative inhibition of SHP-2 phosphatase activity.
To quantify the inhibition of neurite growth, we mea-
sured the lengths of neurites from SCG neurons in dissoci-
ated cell cultures. Wt SCG neurons grew long neurites
(150 m; Fig. 7A), while neurite outgrowth from DN
SHP-2 neurons was minimal. The average neurite length of
DN SHP-2 neurons was only 5% of that observed for wt
neurons (Fig. 7B).
Quantitative analysis of OX SHP-2 neurons confirmed
that neurite growth was near normal, but revealed a subtle
effect of SHP-2 overexpression on neurite growth (Figs. 7C
and 7D). On average OX SHP-2 neurite lengths were 82% of
those for wt neurons (Fig. 7D). These data demonstrate that
SHP-2 activity is required for NGF-dependent neurite
growth from sympathetic neurons in vitro, and also suggest
that increasing SHP-2 protein levels above normal produces
suboptimal signals for neurite formation.
DN SHP-2 Neurons Are NGF-Responsive, and
SHP-2 Is Not Absolutely Required in the NGF
Survival Pathway
Both survival and neurite growth of neonatal sympathetic
neurons in vitro depend on NGF (Campenot, 1977; Cough-
lin et al., 1977; Coughlin and Collins, 1985; Hendry, 1977;
Levi-Montalcini, 1976). In our SCG culture experiments,
numerous DN SHP-2 neurons survived for more than 7
days, suggesting that the neurons remained NGF-
responsive, and that NGF survival pathways were not
inhibited by a decrease in SHP-2 activity. However, quan-
titative assessment revealed that surviving neurons in DN
SHP-2 cultures averaged 33  11% (mean  SEM) of wt
neuronal numbers after 3 days in vitro. Therefore, inhibi-
tion of SHP-2 function had an effect on NGF-dependent
neuronal survival in vitro. In principle, neurons that re-
mained in DN SHP-2 cultures could somehow become
independent of NGF for survival. To test this possibility,
we cultured neonatal SCG neurons (wt and DN SHP-2) in
NGF-supplemented medium for 72 h, then NGF was with-
drawn for 96 h. During the 3-day culture in NGF, we
observed an expected survival of both wt and SHP-2 DN
neurons (Figs. 8A and 8C). Wt neurons formed a dense
network of neurites (Fig. 8A), while DN SHP-2 neurons
displayed sparse neurite outgrowth (Fig. 8C). Similarly,
both wt and SHP-2 DN neurons survived well in SCG
explants, but the number and the length of neurites from
DN SHP-2 explants were greatly reduced compared with wt
explants of comparable area (data not shown). In all cases,
removal of NGF caused progressive neuronal death and the
associated beading and eventual disappearance of neurites.
After 4 days in the absence of NGF, almost all of the
dissociated neurons died, but glial cells (whose survival is
NGF-independent) remained (Figs. 8B and 8D). Neuron
death induced by NGF withdrawal was also evident in SCG
explants (not shown). Thus, the survival of DN SHP-2
neurons is NGF-dependent, implying that an NGF-
dependent survival pathway is functional in a substantial
fraction of these neurons. Thus, about one-third of DN
SHP-2 neurons can survive in an NGF-dependent manner,
while these same neurons are almost completely inhibited
with respect to neurite growth. These data suggest that the
signaling pathway underlying NGF-induced neurite out-
growth requires SHP-2, while the pathway underlying
NGF-dependent survival is much less dependent on SHP-2,
at least for some SCG neurons.
Our in vivo data show that DN SHP-2 SCG neurons
exhibit normal survival, but NGF-dependent survival in
vitro is significantly decreased. One explanation for this
discrepancy is the presence in vivo of other growth factors,
such as NT-3, which is known to mediate survival of a
fraction of SCG neurons and to potentiate survival in the
presence of limiting NGF concentrations (Farinas, 1999;
Belliveau et al., 1997; see also Kobayashi and Matsuoka,
2000). To test this idea, we cultured wt and SHP-2 DN
neurons for 24 h in the presence of NGF, NT-3, and BDNF
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(100 ng/ml each). This cocktail of neurotrophins resulted in
near-normal survival of DN SHP-2 neurons (80 8% of wt),
suggesting that survival of DN SHP-2 neurons in vivo may
result from the presence of multiple neurotrophins with
survival activity on these cells. Interestingly, DN SHP-2
neurons cultured in the neurotrophin cocktail were still
largely inhibited with respect to neurite extension (data not
shown).
SHP-2 Protein Is a Positive Regulator of
NGF-Stimulated ERK Activation
Our results, both in vivo and in vitro, are consistent with
the view that survival and induction of neurite growth
result from distinct pathways, both activated by NGF (see
Zhang et al., 2000), and indicate that SHP-2 is a critical
component of a neurite outgrowth pathway. NGF and other
neurotrophins activate ERKs in neuronal cells (Kaplan and
Miller, 2000; Segal and Greenberg, 1996; Watson et al.,
2001), and activation of ERKs 1 and 2 (ERK1/2) is thought to
be important in the induction of neurite outgrowth (Dim-
itropoulou and Bixby, 2000; Fukuda et al., 1995; Perron and
Bixby, 1999; Schmid et al., 1999). Moreover, for many
polypeptide growth factors (FGF, EGF, PDGF, insulin),
there is evidence that SHP-2 function is required for
ERK1/2 activation (Bennett et al., 1994, 1996; Hadari et al.,
1998; Milarski and Saltiel, 1994; Noguchi et al., 1994;
Rivard et al., 1995; Tang et al., 1995; Yamauchi et al., 1995;
Zhao et al., 1995). Taken together, the data suggest that
ERK activation is a part of a SHP-2 mediated neurite
outgrowth pathway triggered by NGF. As one test of this
idea, we examined whether inhibition of SHP-2 activity,
resulting from DN SHP-2, could inhibit ERK1/2 activation
by NGF in SCG neurons. When NGF was withdrawn from
both wt and DN SHP-2-cultured SCG neurons for 12 h, ERK
activation was low, as demonstrated by immunocytochem-
istry using an antibody specific for phosphorylated (acti-
vated) ERK (Fig. 9D). Acute readdition of NGF to cultures of
wt neurons led to a sharp increase in phospho-ERK staining,
such that intense fluorescence was visible in both cell
bodies and neurites (Fig. 9E). When NGF was added to DN
SHP-2 neuron cultures, however, the abundance of immu-
noreactive phospho-ERK was similar to that in control DN
cultures with no NGF addition (Fig. 9F). More than 92% of
wt SCG neurons exhibited strong phospho-ERK staining
upon acute readdition of NGF (n  183 neurons, 2 experi-
ments), while only 20% of SHP-2 DN neurons exhibited
staining levels above those of non-NGF-treated controls
(n  143 neurons, 2 experiments).
To test ERK activation more quantitatively, we measured
ERK activation by Western blotting with phospho-ERK
antibodies, using total ERK levels as a normalization con-
trol. Both wt and OX SHP-2 neurons showed robust induc-
tion of ERK phosphorylation 3 h after acute NGF addition,
while ERK phosphorylation remained at baseline levels in
DN SHP-2 neurons (Fig. 10). Normalized phospho-ERK
levels were four-fold higher for wt or for OX SHP-2 neurons
after NGF addition, while DN SHP-2 neurons showed
phospho-ERK levels indistinguishable from baseline (Table
1). Thus, SHP-2 activity is required in sympathetic neurons
for ERK activation by NGF. Our findings in primary neu-
rons are in accord with earlier studies in the PC12 cell line
(Wright et al., 1997). Together with our findings that SHP-2
activity is required for NGF-stimulated neurite growth in
sympathetic neurons, these data suggest that a neurite
outgrowth signaling pathway activated by NGF requires
both SHP-2 activity and phosphorylation of ERK1/2. In
FIG. 5. Increased sympathetic innervation of pineal glands in SHP-2 DN mice. Sympathetic innervation of pineal glands was examined
as for submaxillary glands. Animals were injected intraperitoneally with -methyl norepinephrine prior to dissection to saturate
catecholamine levels. (A) Representative section illustrating fluorescence levels in the wt pineal. (B) Representative section illustrating
fluorescence levels in the SHP-2 DN pineal. Fluroescence levels are clearly higher in the SHP-2 DN gland. Similar results were obtained
in three independent experiments. Scale bar, 100 m.
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contrast, survival pathways are less dependent on both
SHP-2 activity and ERK1/2 activation.
DISCUSSION
Using a dominant negative SHP-2 mutant in transgenic
mice, we have begun to define pathways in which SHP-2 is
normally involved during the development of sympathetic
neurons. Inhibition of endogenous SHP-2 function did not
alter survival of sympathetic neurons in vivo. However,
inhibition of SHP-2 reduced NGF-dependent survival of
these neurons in vitro, and SHP-2 function was required in
at least two phases of axon growth. In vitro, expression of a
DN-SHP2 mutant inhibited NGF-dependent neurite out-
growth and the activation of ERK in NGF-dependent sym-
pathetic neurons, though not the initial sprouting of neu-
rites. In vivo, interference with normal SHP-2 signaling
resulted in increased axon density within the targets of
sympathetic innervation. These data are consistent with a
mechanism in which NGF-induced axon extension and
termination within targets requires signaling pathways that
include SHP-2, whereas NGF-induced survival is achieved
by an intracellular signaling pathway that is less dependent
on SHP-2.
Interpretation of our results depends on the degree to
which transgene expression achieves specific inhibition of
SHP-2 function. Several lines of evidence suggest that the
mutation we introduced to mice specifically inhibited en-
dogenous SHP-2 activity. First, the C459S mutant has been
shown to inhibit SHP-2 function as a dominant negative in
a number of independent systems, in vitro (Bennett et al.,
1994, 1996; Milarski and Saltiel, 1994; Noguchi et al., 1994;
Rivard et al., 1995; Yamauchi et al., 1995; Zhao et al.,
1995), and does not appear to nonspecifically influence
other signaling pathways in cultured mammalian cells.
(Araki et al., 2000; Hadari et al., 1998). In PC12 cells, an in
vitro model of sympathetic neurons, DN SHP-2, but not
DN SHP-1 (a closely related SH2-containing PTP) inhibits
NGF-induced neuronal differentiation, even though both
SHP-1 and SHP-2 are phosphorylated in response to NGF.
Importantly, this inhibition is seen with overexpression to
a level similar to that reached in our transgenic animals
(Wright et al., 1997). In addition, overexpression of DN
SHP-2 did not result in reduced viability of sympathetic
neurons or discernable defects in vivo, other than those
noted, as might be expected if the DN protein interacted
nonspecifically with incorrect signaling proteins or path-
ways. Indeed, because sympathetic neurons in which SHP-2
was overexpressed behaved for the most part like wt neu-
rons, it appears that the abnormal aspects of axon and
neurite outgrowth observed in DN SHP-2 neurons were
largely a consequence of a reduced activity of the SHP-2
phosphatase domain.
Our results, both in vitro and in vivo, provide evidence
that NGF activates at least two independent signaling
pathways in sympathetic neurons: a SHP-2-dependent sig-
naling pathway that influences axon outgrowth and a
separate survival signaling pathway that is less dependent
on SHP-2. The existence of independent NGF-activated
signaling pathways is consistent with several previous lines
of evidence. Pharmacological experiments with sympa-
thetic neurons in vitro (Greene et al., 1990) suggest that
distinct mechanisms underlie the respective abilities of
NGF to mediate survival and to promote neurite growth. In
PC12 cells, deletion of the conserved juxtamembrane do-
main of trkA impairs NGF-mediated neurite outgrowth,
but not survival (Peng et al., 1995). In addition, trkA
receptors on PC12 cells mediate NGF-induced survival
through a PI3kinase/Akt module, while internalized recep-
tors regulate NGF-induced differentiation by a PI3 kinase/
Akt-independent mechanism (Zhang et al., 2000). Studies
of the signaling mechanisms in sympathetic neurons have
suggested that NGF-dependent neurite extension, but not
neuron survival, requires the activation of ERKs (Creedon
et al., 1996; Virdee and Tolkovsky, 1996). In our in vitro
experiments, NGF-dependent ERK1/2 phosphorylation, and
NGF-dependent neurite extension were both severely im-
paired in neurons expressing DN SHP-2. The reduced phos-
phorylation, and thus reduced activation of ERK suggests
that SHP-2 acts upstream of ERK in at least one NGF-
activated signaling pathway present in sympathetic neu-
rons. SHP-2 may also be upstream of MEK/ERK activation
in a NGF-activated signaling pathway leading to differen-
tiation of PC12 cells (Wright et al., 1997). Thus, we propose
that NGF-stimulated neurite extension from sympathetic
neurons, in vitro, requires SHP-2-mediated activation of
ERK. This hypothesis is in accord with mounting evidence
that ERK activation is a critical step in the induction of
neurite extension by varying stimuli; these include cell
adhesion molecules and RPTPs, as well as soluble growth
factors and neurotrophins (Dimitropoulou and Bixby, 2000;
Drosopoulos et al., 1999; Perron and Bixby, 1999; Schmid et
al., 1999). Sympathetic neuron survival, in contrast, is
unaffected by DN SHP-2 expression in vivo, and in vitro is
less dependent on SHP-2 function and ERK activation.
Therefore, our results suggest that NGF signaling pathways
underlying neuron survival diverge from a SHP-2-
dependent pathway that mediates axon extension. Al-
though the levels of DN SHP-2 expression we achieved
were strongly inhibitory in this and similar studies, it is
also possible that the SHP-2-dependent survival pathway(s)
requires only low levels of SHP-2 function compared with
neurite growth pathways. It is not clear, however, why only
a fraction (33%) of DN SHP-2 sympathetic neurons sur-
vived in vitro in an NGF-dependent manner. There appear
to be multiple NGF-mediated survival pathways in these
neurons (Kuruvilla et al., 2000); perhaps only one is SHP-2-
dependent.
The ability of NGF to initiate axon extension from
sympathetic neurons in vitro was severely compromised by
expression of DN SHP-2. Therefore, the seemingly normal
initial axon growth from DN SHP-2 sympathetic neurons in
vivo would suggest that NGF is not critical for axon
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extension from sympathetic neurons, in situ. This latter
conclusion is consistent with other in vivo observations.
NGF is primarily synthesized in the targets of sympathetic
innervation, but not until around the time of target inner-
vation (Korsching and Thoenen, 1988), suggesting that axon
outgrowth to sympathetic targets is largely NGF-
FIG. 7. Quantification of NGF-induced neurite outgrowth from dissociated SCG neurons. (A) Paired SCGs from individual neonatal mice
in a single litter (6 wt and 3 SHP-2 DN mice) were cultured for 24 h. Average neurite lengths were measured for at least 20 randomly selected
neurons in each culture, and the data were plotted as mean SEM. The presence of the SHP-2 DN transgene inhibits neurite growth almost
completely. (B) Normalized data from 3 independent experiments (total of 12 wt, 8 DN cultures) performed as in (A). Overexpression of DN
SHP-2 resulted in a 95% inhibition of neurite growth. (C) Paired SCGs from individual neonatal mice in a single litter (6 wt and 4 SHP-2
OX mice) were cultured for 24 h. Average neurite lengths were measured for at least 20 randomly selected neurons in each culture, and the
data were plotted as mean  SEM. Neurite lengths in SHP-2 OX cultures are roughly comparable to those in controls (D) Normalized data
from 2 independent experiments (total of 9 wt, 10 OX cultures) performed as in (C). The data reveal a small (19%) but statistically
significant inhibition of neurite growth by overexpression of wt SHP-2. *, P  0.001.
FIG. 6. NGF-stimulated neurite outgrowth from cultured sympathetic neurons. SCGs from neonatal mice were partially dissociated and
cultured on poly-D-lysine/laminin substrates for 24 h in medium supplemented with 100 ng/ml NGF prior to examination. (A) Dissociated
SCG neurons from a wt mouse grow extensive networks of neurites under these conditions. (E) Similar numbers of dissociated neurons
(black arrowheads) are present in a culture from a SHP-2 DN littermate, but neurites are essentially absent. (B) A ganglionic explant from
a wt mouse exhibits a dense halo of long neurites. (F) A ganglionic explant from a SHP-2 DN littermate shows sparse neurite growth, even
though the size of the explant is similar. (C) Dissociated SCG neurons from a second wt mouse also grow extensive networks of neurites.
(G) Dissociated neurons from a SHP-2 OX littermate exhibit a similar degree of neurite growth. (D) A ganglionic explant from a second wt
mouse exhibits a dense halo of long neurites. (H) A ganglionic explant from a SHP-2 OX littermate exhibits similar neuritic growth. Thus,
SHP-2 DN SCGs, but not SCGs overexpressing wt SHP-2, are deficient in NGF-dependent neurite outgrowth. Similar results were observed
in 19 experiments on 3 different SHP-2 DN lines, and in 11 experiments on 3 SHP-2 OX lines. Scale bar, 100 m.
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independent. Branching of sympathetic axons, however,
occurs mainly within NGF-rich target tissues, rather than
during the extension of sympathetic axons from ganglia to
target tissues (Rubin, 1985). In vivo, therefore, NGF may
control axon branching and termination within targets, but
not outgrowth from sympathetic neurons per se.
Because NGF-initiated signals are required for the sur-
vival of most wt sympathetic neurons in vivo, information
regarding the importance these signals may have during
axon extension is difficult to ascertain from the analysis of
NGF-, TrkA-, or p75- (low affinity NGF receptor) null
mouse mutants. Sympathetic neurons in trkA-deficient
mice fail to innervate the submandibular gland, even
though they innervate more proximal targets. This could
reflect the loss of a NGF-activated process in sympathetic
axons growing to distal targets, but may rather reflect the
survival-promoting effects of NGF (and possibly NT-3 act-
ing through trkA), such that neurons are not viable long
enough to innervate distal targets (Fagan et al., 1996;
Francis and Landis, 1999). Indeed, normal extension of
axons to target tissues may depend on the activation of trkA
receptors by other neurotrophins, such as NT-3, rather than
NGF (Belliveau et al., 1997; White, 1998; Francis et al.,
1999). NT-3 is more effective at stimulating sympathetic
neuron neurite outgrowth than survival (Belliveau et al.,
1997). In the case of sensory neurons, analysis of mice
lacking both trkA and the proapoptotic protein Bax suggest
that trkA activation is required for growth of peripheral
axon branches (Patel et al., 2000). We have preliminary
evidence that NT-3 (together with BDNF) increased sur-
FIG. 8. Sympathetic neurons overexpressing DN SHP-2 are dependent on NGF for survival in vitro. SCG neurons were cultured in the
presence of 100 ng/ml NGF for 72 h; NGF was then removed prior to culture for an additional 96 h. Phase-contrast microphotographs of
identical fields were taken immediately before and 96 h after NGF withdrawal. (A) Control (wt) dissociated neurons exhibit a dense network
of processes prior to NGF withdrawal. (B) This same field is devoid of neurons 96 h after NGF withdrawal. (C) SHP-2 DN neurons have
normal, phase-bright cell bodies after 72 h (black arrowheads), but process outgrowth is sparse (compare with A). (D) The neurons have
disappeared 96 h after NGF withdrawal. Scale bar, 40 m.
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vival of DN SHP-2 neurons in vitro, without a major effect
on neurite growth. These results are consistent with the
idea that trkA-dependent survival signaling is less depen-
dent on SHP-2 than the neurite growth pathway.
Although other neurotrophins may influence axon
growth, innervation within targets by sympathetic neurons
is clearly NGF-dependent. Sympathetic neuron innervation
densities within target tissues correlate directly with the
local concentrations of NGF (Korsching and Thoenen, 1983;
Shelton and Reichardt, 1984). Moreover, overproduction of
NGF in target tissues leads to increased densities of sym-
pathetic innervation (Albers et al., 1994; Edwards et al.,
1989; Hassankhani et al., 1995). NGF also promotes termi-
nal branching of sensory axons (Diamond et al., 1987; Gallo
FIG. 9. DN SHP-2 inhibits NGF-stimulated ERK activation in sympathetic neurons. Neonatal SCG neurons were cultured in the presence
of 100 ng/ml NGF for 6 days, withdrawn from NGF for 12 h, and acutely stimulated by addition of 100 ng/ml NGF 3 h prior to fixation
and staining. ERK activation was monitored by immunofluorescence using a phospho-specific antibody to ERK1/2 Left panels (A–C) are
phase-contrast microphotographs; (D–F) Corresponding fluorescence images showing phospho-ERK staining. (A, D) Controls in which
SHP-2 DN SCG neurons were withdrawn from NGF without acute readdition. (B, E) Wt neurons show strongly stained cell bodies as well
as stained processes (white arrowheads). (C, F) Levels of staining in SHP-2 DN neurons after NGF addition are comparable with those seen
in controls (compare D and F). Similar results were seen in 3 independent experiments. Scale bar, 100 m.
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and Letourneau, 1998; Owen et al., 1989). Interestingly,
overexpression of NGF in sympathetic neurons in mice
leads to hypertrophy of sympathetic ganglia, an increase in
the total number of sympathetic axons, but a marked
decrease of innervation density in target tissues. The de-
creased innervation of targets in mice can be overcome by
simultaneous overexpression of NGF in target tissues
(Hoyle et al., 1993). This was interpreted by the authors to
suggest that a gradient of NGF (high levels in targets, low
levels in nerve) is required for appropriate innervation of
target tissues. NGF expression in nerve fibers would disrupt
the gradient, but a gradient could be partially restored by
overexpression of NGF in targets. This idea can help ex-
plain the results of DN SHP-2 expression in sympathetic
neurons. We hypothesize that after reaching the target,
neurons grow into the target and branch influenced by an
NGF gradient, and presumably also stimulated by growth
signals from other neurotrophins (see below). Terminal
branches would stop growing when they detect an appro-
priate level of NGF within the gradient. In DN SHP-2
sympathetic neurons, although appropriate levels of NGF
would be “seen,” downstream signaling that elicits axon
termination would be greatly inhibited.
In vitro studies suggest that the control of sympathetic
axon outgrowth by neurotrophins is complex. Antagonistic
interactions between the TrkA and p75 neurotrophin recep-
tors regulate sympathetic neuron axon extension and target
innervation (Kohn et al., 1999). In addition, a number of
growth factors and neurotrophins induce neurite outgrowth
from sympathetic neurons. These include IGFs, insulin,
NT-3, and BDNF (Recio-Pinto et al., 1986; Zackenfeld et
al., 1995; Belliveau et al., 1997; Botchkarev et al., 1998).
Any one or all of these may provide influence to extending
axons in vivo. In addition, cellular adhesion molecules,
extracellular matrix proteins, and RPTPs are known to
influence axon extension from neurons, at least in vitro.
Hence, any number of environmental cues may influence
axon outgrowth at any one time. In vitro experiments will
not satisfactorily mimic all the influences at work on
extending axons in vivo. Our results stress that interpreta-
tion of in vivo function from in vitro assays is not always
straightforward. DN SHP-2 expression inhibited sympa-
thetic neurite growth in vitro, but unexpectedly increased
sympathetic innervation levels in vivo.
The mechanism through which DN-SHP2 inhibited
NGF-stimulated neurite outgrowth in vitro, yet led to
excessive axon growth in sympathetic targets in vivo, is not
clear. At least three mechanisms likely contribute to this
finding. First, whether a guidance cue such as NGF is
FIG. 10. DN SHP-2, but not OX SHP-2, inhibits NGF activation of ERK1/2 in sympathetic neurons. SCG neurons, either wt, DN SHP-2
(DN), or OX SHP-2 (OX), were cultured and stimulated with NGF as described in Fig. 9. Neuronal extracts were subjected to SDS-PAGE
and Western blotting. Membranes were probed with a phosphospecific ERK antibody (phospho-ERK), then stripped and reprobed with a
pan-ERK1/2 antibody (total ERK) as a normalization control. Robust stimulation of both p44 ERK1 and p42 ERK2 is apparent in the wt and
OX lanes after NGF stimulation, while the DN lane is similar to the NGF control.
TABLE 1
Quantification of Phospho-ERK Activation by NGF
Neurons
(condition) pERK/tERK Fold stimulation
(NGF) 4.8  1.3 NA
wt (NGF) 20  3.3 4.0
DN SHP-2 (NGF) 5  0.8 1.0
OX SHP-2 (NGF) 21 4.3
Note. SCG culture and NGF stimulation were performed on
cultured neurons as described in Fig. 9. Protein extracts from
untreated or NGF-treated cultures were subjected to SDS-PAGE
and Western blotting with phospho-ERK antibodies, followed by
stripping of the membrane and reprobing with pan-ERK antibodies
as a normalization standard. ERK bands were quantified by using
NIH Image, and the ratio of phospho-ERK (pERK) to total ERK
(tERK) was calculated. N  3 (NGF), or 2 (wt, DN SHP-2;NGF);
the OX SHP-2 data are from a single experiment.
184 Chen et al.
© 2002 Elsevier Science (USA). All rights reserved.
attractive or repulsive to growth cones depends on the other
signals impinging on this growth cone (Hopker et al., 1999).
As noted above, these signals are extraordinarily complex
for sympathetic neurons. Second, exposure of the entire
neuron to a constant concentration of NGF is very different
from exposure of the axon terminals to a gradient of this
protein. Recent evidence makes clear, for example, that
signals from NGF arising in the terminal differ from those
arising in the cell body (Kuruvilla et al., 2000; Watson et al.,
2001). Finally, overgrowth of sympathetic fibers in vivo
may involve NGF-independent, SHP-2-dependent pathways
in addition to the NGF pathway.
In sum, our data indicate that SHP-2 participates in
signaling pathways, initiated by NGF, that regulate axon
extension and termination of axons within targets of sym-
pathetic innervation. The SHP-2-dependent pathway that
mediates neurite outgrowth also leads to activation of
ERK1/2, and is distinct from NGF-activated survival signal-
ing pathways in sympathetic neurons. Using an in vivo
approach, we have demonstrated that SHP-2 is also required
to respond to target-generated factors, presumably includ-
ing NGF, which provide a “cessation signal” to branching
axons extending from sympathetic neurons. Thus, it would
appear that SHP-2 is involved in multiple steps in the
growth of sympathetic axons. We propose that sympathetic
neurons during development use a SHP-2/ERK signaling
pathway to interpret their spatial position within NGF
gradients. Further experiments will be required to test this
model and identify possible interactions with other signal-
ing pathways that modulate the response of sympathetic
axons to NGF.
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